Biotherapeutics, Inc.

Timeline

1. Sep 18, 2026 Grant Government grant — SBIR: $500,000 (annual award, as published), announced Sep 18, 2026. Agency: NIH/NIA. Source: government award database. source ↗
2. Sep 17, 2026 Grant Government grant — SBIR: $191,331 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
3. Aug 24, 2026 Grant Government grant — SBIR: $314,363 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
4. Aug 13, 2026 Grant Government grant — SBIR: $314,363 (annual award, as published), announced Aug 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
5. Sep 22, 2025 Grant Government grant — SBIR: $1.85M (annual award, as published), announced Sep 22, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗
6. Aug 5, 2025 Grant Government grant — SBIR: $314,363 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
7. Aug 4, 2025 Grant Government grant — SBIR: $314,363 (annual award, as published), announced Aug 4, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
8. Jun 20, 2025 Grant Government grant — SBIR: $359,625 (annual award, as published), announced Jun 20, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
9. Jan 14, 2025 Grant Government grant — SBIR: $347,608 (annual award, as published), announced Jan 14, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Funding

Last 2 years.

• Sep 18, 2026 Government grant — SBIR: $500,000 (annual award, as published), announced Sep 18, 2026. Agency: NIH/NIA. Source: government award database. source ↗
• Sep 17, 2026 Government grant — SBIR: $191,331 (annual award, as published), announced Sep 17, 2026. Agency: NIH/NIAMS. Source: government award database. source ↗
• Aug 24, 2026 Government grant — SBIR: $314,363 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
• Aug 13, 2026 Government grant — SBIR: $314,363 (annual award, as published), announced Aug 13, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
• Sep 22, 2025 Government grant — SBIR: $1.85M (annual award, as published), announced Sep 22, 2025. Agency: NIH/NIAMS. Source: government award database. source ↗
• Aug 5, 2025 Government grant — SBIR: $314,363 (annual award, as published), announced Aug 5, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
• Aug 4, 2025 Government grant — SBIR: $314,363 (annual award, as published), announced Aug 4, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
• Jun 20, 2025 Government grant — SBIR: $359,625 (annual award, as published), announced Jun 20, 2025. Agency: NIH/NIDDK. Source: government award database. source ↗
• Jan 14, 2025 Government grant — SBIR: $347,608 (annual award, as published), announced Jan 14, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

NIH awards 26

Annual award amounts. Total $9.4M.

• Sep 17, 2024 NIH award 1R43HL172516-01 FY2024: $355,935 awarded for that fiscal year; activity R43 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Novel Immunoregula source ↗
• Aug 20, 2024 NIH award 1R43HL176386-01 FY2024: $288,986 awarded for that fiscal year; activity R43 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Novel Therapeutics source ↗
• Jun 27, 2024 NIH award 1R43AI184008-01A1 FY2024: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Comparative Efficacy of Therapeutic source ↗
• Sep 20, 2023 NIH award 1R43AR083730-01 FY2023: $295,294 awarded for that fiscal year; activity R43 (SBIR); PI TUBAU-JUNI, NURIA; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. A First-in-class Topical Immunoregulato source ↗
• Sep 7, 2023 NIH award 1R43AR082207-01A1 FY2023: $295,924 awarded for that fiscal year; activity R43 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Novel first-in-class Therapeuti source ↗
• Sep 5, 2023 NIH award 1R43AR082756-01 FY2023: $295,924 awarded for that fiscal year; activity R43 (SBIR); PI TUBAU-JUNI, NURIA; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Novel Topical Therapeuti source ↗
• Jun 8, 2023 NIH award 5R44AI156952-03 FY2023: $563,659 awarded for that fiscal year; activity R44 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Novel Immunoregulatory Therapeutics for Sys source ↗
• Apr 14, 2023 NIH award 1R43DK135158-01A1 FY2023: $356,068 awarded for that fiscal year; activity R43 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Immunoregulatory Therapeutics for Ulcerat source ↗
• Jun 27, 2022 NIH award 2R44AI156952-02 FY2022: $563,659 awarded for that fiscal year; activity R44 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Novel Immunoregulatory Therapeutics for Sys source ↗
• Jul 27, 2021 NIH award 1R43HL160260-01 FY2021: $361,510 awarded for that fiscal year; activity R43 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Targeting the Immunometabolic Hub source ↗
• Jun 28, 2021 NIH award 5R44DK120338-03 FY2021: $419,987 awarded for that fiscal year; activity R44 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Effects of Abscisic Acid on Insulin S source ↗
• Jun 11, 2021 NIH award 1R43AI165190-01 FY2021: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. The First LANCL2-based therapeutic fo source ↗
• Jun 4, 2021 NIH award 5R44DK121561-03 FY2021: $643,417 awarded for that fiscal year; activity R44 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Validation of Immunometabolic NLRX1 Therape source ↗
• Dec 21, 2020 NIH award 1R43AI156952-01 FY2021: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Novel Immunoregulatory Therapeutics for Sys source ↗
• Aug 18, 2020 NIH award 1R43AT010991-01 FY2020: $295,453 awarded for that fiscal year; activity R43 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. The First Pomegranate Seed Oil-Contai source ↗
• Jul 1, 2020 NIH award 1R43CA254616-01 FY2020: $230,729 awarded for that fiscal year; activity R43 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Developing Novel NLRX1-Based Immuno-Oncolog source ↗
• Jun 25, 2020 NIH award 4R44DK120338-02 FY2020: $933,303 awarded for that fiscal year; activity R44 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Effects of Abscisic Acid on Insulin S source ↗
• May 12, 2020 NIH award 2R44DK121561-02 FY2020: $634,825 awarded for that fiscal year; activity R44 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Validation of Immunometabolic NLRX1 Therape source ↗
• Apr 24, 2020 NIH award 1R43AI152584-01 FY2020: $231,195 awarded for that fiscal year; activity R43 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Novel Immunoregulatory Drugs for Type 1 Dia source ↗
• Jun 28, 2019 NIH award 1R43AI145361-01A1 FY2019: $299,984 awarded for that fiscal year; activity R43 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Antibiotic-Free Clos source ↗
• Apr 22, 2019 NIH award 1R44DK120338-01A1 FY2019: $281,612 awarded for that fiscal year; activity R44 (SBIR); PI HONTECILLAS, RAQUEL; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Effects of Abscisic Acid on Insulin source ↗
• Mar 21, 2019 NIH award 1R43DK121561-01 FY2019: $233,239 awarded for that fiscal year; activity R43 (SBIR); PI LEBER, ANDREW; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Immunometabolic NLRX1 Therapeutics for IBD source ↗
• Aug 21, 2018 NIH award 1R44AI134163-01A1 FY2018: $299,576 awarded for that fiscal year; activity R44 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. BT-11: A First-in-class Oral Th source ↗
• Aug 17, 2016 NIH award 1R43DK109836-01A1 FY2016: $250,000 awarded for that fiscal year; activity R43 (SBIR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. The First Abscisic Acid-Contain source ↗
• Sep 16, 2013 NIH award 1R41DK099027-01A1 FY2013: $188,333 awarded for that fiscal year; activity R41 (STTR); PI BASSAGANYA-RIERA, JOSEP; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Novel LANCL2-bas source ↗
• Jul 15, 2013 NIH award 1R43DK097940-01A1 FY2013: $148,288 awarded for that fiscal year; activity R43 (SBIR); PI CARTER, KEN; recipient as written: BIOTHERAPEUTICS, INC., Blacksburg, VA. Development of Novel Class of Anti-Inflamma source ↗